Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466094 | 0.87 | ALDH1A1 (0.50) | ALDH1A1TBXA2RNPSR1MAPTKMT2A | |
| SCHEMBL8724177 | 0.83 | SRD5A2 (0.61) | ALDH1A1HPGDMAPTKMT2AMEN1 | |
| SCHEMBL2616111 | 0.80 | MAPK1 (0.56) | ALDH1A1NR1H4MAPTKMT2AMEN1 | |
| SCHEMBL4466049 | 0.80 | CA12 (0.42) | ALDH1A1HPGDNPSR1NR1H4KMT2A | |
| SCHEMBL10629949 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TBXA2RHPGDMAPTKMT2A | |
| SCHEMBL22966218 | 0.79 | ALDH1A1 (0.52) | ALDH1A1TBXA2RHPGDNPSR1MAPT | |
| SCHEMBL4235361 | 0.79 | ALDH1A1 (0.51) | ALDH1A1TBXA2RMAPTKMT2AMEN1 | |
| SCHEMBL22966227 | 0.79 | ALDH1A1 (0.54) | ALDH1A1TBXA2RMAPTKMT2AMEN1 | |
| SCHEMBL10771835 | 0.78 | HSPB1 (0.51) | ALDH1A1TBXA2RNPSR1MAPTKMT2A | |
| SCHEMBL5592550 | 0.78 | ALDH1A1 (0.60) | ALDH1A1HPGDMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585869-B2 | Substituted heterocylces for the treatment of abnormal cell growth | PFIZER, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1636195-A1 | QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106308-A1 | QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | PFIZER INC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242604-A1 | Substituted heterocycles for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNY | ALDH1A1 237/4885TBXA2R 1889/4885HPGD 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.